000109538 001__ 109538
000109538 005__ 20230519145558.0
000109538 0247_ $$2doi$$a10.3389/fcimb.2021.633162
000109538 0248_ $$2sideral$$a127170
000109538 037__ $$aART-2021-127170
000109538 041__ $$adeu
000109538 100__ $$aFreire-Salinas, Javier
000109538 245__ $$aGenotype distribution change after Human Papillomavirus vaccination in two autonomous communities in Spain
000109538 260__ $$c2021
000109538 5060_ $$aAccess copy available to the general public$$fUnrestricted
000109538 5203_ $$aContextIt has been more than 10 years since the human papillomavirus (HPV) vaccination program was initiated in most advanced countries. Thus, it seems necessary to change the uterine cervical cancer screening strategy. Molecular-based tests are considered essential in this scenario.ObjectiveWe aimed to review the distribution of the HPV genotypes after the introduction of the vaccination program with Cervarix® and Gardasil 4® in two autonomous communities in Spain, looking for possible changes in distribution and the occurrence of a herd effect.DesignA cross-sectional study was performed in 45,362 samples that were processed in the Cantabria and Aragon communities during the period from 2002 to 2016. We compared the genotype distribution before and after the vaccination program was initiated.ResultsGenotypes HPV6 and HPV11 have decreased significantly after the introduction of the vaccine. HPV16 has had a decrease, but not a significant one in the statistical analysis. However, HPV31, HPV52, and HPV45 have increased in percentage. A replacement phenomenon with other genotypes not included in the vaccine has been observed in our population.ConclusionsContinued surveillance is needed to provide further indication of any changes over time in the genotypes in circulation. This will be facilitated by monitoring the genotyping results from the new model of cervical screening using primary HPV DNA testing.
000109538 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000109538 590__ $$a6.073$$b2021
000109538 592__ $$a1.389$$b2021
000109538 594__ $$a5.9$$b2021
000109538 591__ $$aMICROBIOLOGY$$b33 / 138 = 0.239$$c2021$$dQ1$$eT1
000109538 593__ $$aImmunology$$c2021$$dQ1
000109538 591__ $$aIMMUNOLOGY$$b53 / 163 = 0.325$$c2021$$dQ2$$eT1
000109538 593__ $$aMicrobiology (medical)$$c2021$$dQ1
000109538 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000109538 593__ $$aInfectious Diseases$$c2021$$dQ1
000109538 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000109538 700__ $$0(orcid)0000-0001-5134-1006$$aBenito, Rafael$$uUniversidad de Zaragoza
000109538 700__ $$aAzueta, Ainara
000109538 700__ $$0(orcid)0000-0002-2037-3213$$aGil, Joaquina
000109538 700__ $$aMendoza, Claudia
000109538 700__ $$aNicolás, Montserrat
000109538 700__ $$aGarcía-Berbel, Pilar
000109538 700__ $$0(orcid)0000-0002-0036-6630$$aAlgarate, Sonia$$uUniversidad de Zaragoza
000109538 700__ $$aGómez-Román, Javier
000109538 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000109538 773__ $$g11 (2021), 663162$$tFrontiers in Cellular and Infection Microbiology$$x2235-2988
000109538 8564_ $$s455912$$uhttps://zaguan.unizar.es/record/109538/files/texto_completo.pdf$$yVersión publicada
000109538 8564_ $$s2135460$$uhttps://zaguan.unizar.es/record/109538/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000109538 909CO $$ooai:zaguan.unizar.es:109538$$particulos$$pdriver
000109538 951__ $$a2023-05-18-15:58:04
000109538 980__ $$aARTICLE